Avoid common mistakes on your manuscript.
Correction to: Cardiovascular Intervention and Therapeutics https://doi.org/10.1007/s12928-020-00719-6
In the original publication of the article, Fig. 4(B) and 4(C) were published incorrectly. The correct figures are given in this correction.
The effect of 1-month DAPT relative to 12-month DAPT stratified by CYP2C19 genotypes. Effects of 1-month versus 12-month DAPT for the primary and major secondary endpoints stratified by a three CYP2C19 genotypes (PM, IM, and EM), b PM/IM and EM (with or without CYP2C19*2 or *3 LOF allele), c with or without CYP2C19*2 LOF allele, and d with or without CYP2C19*3 LOF allele. CI, confidential interval; DAPT, dual antiplatelet therapy; EM, extensive metabolizer; HR, hazard ratio; IM, intermediate metabolizer; LOF, loss-of-function; and PM, poor metabolizer
Author information
Authors and Affiliations
Consortia
Corresponding author
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Watanabe, H., Morimoto, T., Ogita, M. et al. Correction to: Influence of CYP2C19 genotypes for the effect of 1‑month dual antiplatelet therapy followed by clopidogrel monotherapy relative to 12‑month dual antiplatelet therapy on clinical outcomes after percutaneous coronary intervention: a genetic substudy from the STOPDAPT‑2. Cardiovasc Interv and Ther 36, 416–417 (2021). https://doi.org/10.1007/s12928-020-00741-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12928-020-00741-8